Physician profile
Sunil Prem
NPI 1417038746
$1,294.84
in general payments reported to CMS, 2019-2025
13 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.09 · 2020: $15.00 · 2021: $59.18 · 2022: $376 · 2023: $284 · 2024: $341 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.73 |
| Education | $131.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $653.30 | 2020-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Otsuka America Pharmaceutical, INC. | $190.44 | 2023-2024 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $151.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.08 | 2022-2023 | |
| Alpha Cognition USA, INC. | $56.52 | 2025 | Zunveyl |
| Kowa Pharmaceuticals America, INC. | $36.65 | 2023 | Livalo, Seglentis |
| Lundbeck LLC | $31.44 | 2025 | Rexulti |
| Biogen, INC. | $22.77 | 2021 | |
| Eisai INC. | $18.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.09 | 2019 | |
| Ucb, INC. | $17.82 | 2021 | |
| Pfizer INC. | $17.66 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.89 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Prem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.